Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.
Am J Surg Pathol. 2020 Apr;44(4):503-508. doi: 10.1097/PAS.0000000000001393.
The distinction of metastatic melanoma from melanocytic nevi in lymph nodes can on occasion be difficult. As diffuse immunohistochemical (IHC) PRAME (PReferentially expressed Antigen in MElanoma) expression is detected in the majority of primary and metastatic melanomas, but rarely in nevi, we reasoned that PRAME could be a useful adjunct marker for the diagnosis of melanocytes in lymph nodes. In this study, we examined 45 nodal melanocytic deposits comprising 30 nodal nevi and 15 melanoma metastases. The latter were diagnostically not straightforward because they either coexisted with nodal nevi or were present in perinodal fibrous tissue. All nodal nevi (30/30) were negative for PRAME, whereas all melanoma metastases (15/15) were diffusely positive for PRAME IHC. We additionally report the novel use of a PRAME/Melan A dual-label immunostain. Our results show that PRAME IHC may be useful in the assessment of diagnostically challenging nodal melanocytic deposits, such as intraparenchymal nodal nevi, metastases confined to the capsular fibrous tissue, or in the setting of small metastases coexisting with a nodal nevus in the same lymph node.
淋巴结中转移性黑色素瘤与黑色素细胞痣的鉴别有时较为困难。由于弥漫性免疫组化(IHC)PRAME(黑色素瘤中优先表达的抗原)在大多数原发性和转移性黑色素瘤中均有表达,但在痣中很少见,因此我们推测 PRAME 可能是诊断淋巴结中黑色素细胞的有用辅助标志物。在这项研究中,我们检查了 45 个淋巴结黑色素细胞沉积物,包括 30 个淋巴结痣和 15 个黑色素瘤转移灶。后者的诊断并不简单,因为它们要么与淋巴结痣并存,要么存在于淋巴结周围纤维组织中。所有淋巴结痣(30/30)均为 PRAME 阴性,而所有黑色素瘤转移灶(15/15)均为 PRAME IHC 弥漫性阳性。我们还报告了 PRAME/Melan A 双重免疫染色的新用途。我们的结果表明,PRAME IHC 可能有助于评估具有诊断挑战性的淋巴结黑色素细胞沉积物,例如脑实质内淋巴结痣、局限于包膜纤维组织的转移灶,或在同一淋巴结中存在与淋巴结痣并存的小转移灶的情况下。